This presentation highlights the therapeutic possibilities of Axiomer platform that are not limited to disease causing mutations and can potentially address high unmet medical needs by editing wild-type RNA to engineer proteins or modify their function as well as creating de novo mutations.
… platform for the exchange and sharing of insights and innovations to drive the future of clinical development in … platform for the exchange and sharing of insights and innovations to drive the future of clinical development in …
… Unlocking the Potential of Innovative Editing Oligonucleotides to Address Liver … Officer since 2022, following his tenure as Chief Innovation Officer from 2014 to 2022. Gerard has an extensive … and development and is currently in charge of our Innovation unit. Axiomer ® , an RNA editing platform, uses …
… of our collaboration with Lilly. Lilly is a leader in innovative RNA science, making them a great partner for our … developing the medicines of tomorrow takes time, sustained innovation and most importantly, collaboration. Andrew C. …
ProQR has announced the completion of an in-depth strategic review designed to deliver on our commitment to advance RNA therapies for diseases with high unmet need. We are also sharing additional analyses of the sepofarsen Illuminate trial.
… her colleagues applied what she describes as “the amazing innovative retinal organoid model of ‘optic cups’.” She … and scientific chemistry”. Patricia insists that innovation can only be born in environments without …
